It is now customary to treat men with newly diagnosed advanced prostate cancer with Lupron and Docetaxel. In a major advance, we now know adding the androgen blocking drugs abiraterone or … more

Immunotherapy has an interesting status in prostate cancer treatment research. It has attracted some of the best minds in prostate cancer research and motivated innovative laboratory and clinical … more

The processes involved in cancer treatment are and the greater the odds you will defeat your enemy. As you read this issue, consider how you might use additional testing to improve your treatment … more

This issue is devoted to the first successful theranostic treatment for prostate cancer.

The strategy involves a two step approach and derives it's name from the combination of the terms … more

Intro:

This issue offers a concise overview of the major trends in radiation therapy. This is timely as some of these advances are already altering treatment in a major way.

From the patient's … more

We only have one FDA-approved immunotherapy for prostate cancer, Provenge (sipuleucel-T). However, that may be about to change. Research on how to harness the immune system to treat cancer is … more

This issue is focused on when to use Taxotere (docetaxel) chemotherapy. Taxotere (docetaxel) is most commonly used after hormonal therapy options have lost their effectiveness.

However, the CHAARTED … more

This issue is focused on the PSMA scan, which represents a major advance in prostate cancer imaging. This technique allows us to image prostate cancer metastases to bone and other sites down to 2-4 … more